Share chart Organon & Co.
Extended chart
Simple chart
About Organon & Co.
Organon & Co., научно-фармацевтическая компания, разрабатывает и поставляет решения для здоровья через портфель рецептурных терапий в области женского здоровья, биосимиляров и известных брендов. В ее портфель товаров для женского здоровья входят противозачаточные средства и бренды для лечения бесплодия, такие как Nexplanon / Implanon, обратимые противозачаточные средства длительного действия. more detailsMain settings
IPO date
2021-06-02
ISIN
US68622V1061
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
9.82
Дивиденд ао
0.02
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 0.6039 | 10 |
| P/BV | 8.19 | 1 |
| P/E | 4.48 | 10 |
Efficiency
| Title | Value | Grade |
| ROA | 6.87 | 2 |
| ROE | 429.85 | 10 |
| ROIC | 13.88 | 4 |
Dividends
| Title | Value | Grade |
| Dividend yield | 7.58 | 10 |
| DSI | 0.9286 | 9.29 |
| Average dividend growth | 20 | 10 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 5.51 | 0 |
| Debt/Ratio | 0.6778 | 9 |
| Debt/Equity | 18.81 | 0 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | -20.91 | 0 |
| Yield Ebitda, % | -45.06 | 0 |
| Yield EPS, % | -60.91 | 0 |
Dividends
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 10.07 $ | 0 $ | 0 $ | -0.35 % | 0 % | 0 % |
| Week | 9.56 $ | 9.76 $ | 10.08 $ | 4.97 % | 0 % | 0 % |
| Month | 8.69 $ | 8.43 $ | 10.08 $ | 15.48 % | 0 % | 0 % |
| Three month | 12.64 $ | 8.04 $ | 15.79 $ | -20.61 % | 0 % | 0 % |
| Half a year | 14.94 $ | 8.04 $ | 16.41 $ | -32.83 % | 0 % | 0 % |
| Year | 23.03 $ | 8.04 $ | 23.03 $ | -56.43 % | 0 % | 0 % |
| 3 years | 30.5 $ | 8.04 $ | 35.86 $ | -67.1 % | 0 % | 0 % |
| 5 years | 0 $ | 8.04 $ | 38.9 $ | 0 % | 0 % | 0 % |
| 10 years | 0 $ | 8.04 $ | 38.9 $ | 0 % | 0 % | 0 % |
| Year to date | 15.28 $ | 8.04 $ | 16.41 $ | -34.33 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Commission, % |
| iShares Morningstar Small-Cap Value ETF | 0.21823 | 173.73 | 0.06 |
| Syntax Stratified SmallCap ETF | 0.18706 | -2.2 | 0.40 |
| Pacer BioThreat Strategy ETF | 0.17162 | 6.83 | 0.7 |
| iShares Morningstar Small-Cap ETF | 0.1074 | 295.15 | 0.25 |
| 0.17 | 118.38 | 0.35 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Kevin Ali | CEO & Director | 3.96M | 1960 (65 years) |
| Mr. Matthew M. Walsh | Executive VP & CFO | 1.84M | 1967 (58 years) |
| Ms. Rachel A. Stahler | Executive VP & Chief Information Officer | N/A | 1976 (49 years) |
| Ms. Jennifer Halchak | Head of Investor Relations | N/A | |
| Ms. Susanne Gabriele Fiedler | Executive VP & Chief Commercial Officer | 1.44M | 1968 (57 years) |
| Mr. Joseph T. Morrissey Jr. | Executive VP and Head of Manufacturing & Supply | 1.54M | 1965 (60 years) |
| Mr. Kirke Weaver | Executive VP, General Counsel & Corporate Secretary | N/A | 1974 (51 year) |
| Ms. Rebecca Lowell Edwards | Chief Communications Officer | N/A | |
| Mr. Daniel Karp | Chief Business Development Officer | N/A | 1978 (47 years) |
| Ms. Susan O'Neal | Chief Ethics & Compliance Officer |
About company
Address: United States, Jersey City, 30 Hudson Street - Open in google maps, Open in yandex maps
Website: https://www.organon.com
Website: https://www.organon.com
